NCT06750484 - Trial of Trastuzumab Deruxtecan in Previously Treated HER2 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Breast Cancer Metastatic

Interventions

DRUG

Trastuzumab Deruxtecan

Participants will receive the study drug trastuzumab deruxtecan (T-DXd) by IV infusion every 21 days. The number of treatment cycles will depend on how participants respond to treatment.

Trial Locations (1)

06511

RECRUITING

Yale University, New Haven